FDA issues a new warning about popular diabetes drug June 10, 2016By Christine BlankFDA approves a new indication, then issues strengthened warning about possible effects. FDA panel favors combo IR opioidWhile the panel recommended approval of the new product, it did not find sufficient evidence for abuse-deterrent labeling. COPD and pharmacotherapy for smoking cessation at the VA: StudyUse of tobacco-cessation therapy was low. The study found several negative factors — and two positive predictors. Umeclidinium triple therapy for patients with COPD: Two studiesBoth studies demonstrated statistical improvements in trough FEV1 at day 85. 'I love my job,' says UCSF expert in HIV/AIDS, HCVBetty J. Dong, clinician, researcher, professor, and recipient of many honors, talks about her practice of pharmacy and public health. New discoveries, treatments help cancer patients live longer, fuller livesExperts say that value-based medicine is a main theme in cancer care today, and that applies to more than the cost of care. FDA no longer supports use of niacin, fenofibric acid with statinsFDA has withdrawn its approval for niacin and fenofibric acid use with statins to treat high cholesterol. FDA approves PAH treatmentSelexipag is a first-in-class oral treatment option to reduce progression and hospitalization for pulmonary arterial hypertension. Fall-related ICH incidence in elderly on warfarinA study of nearly 32,000 aging veterans revealed the unsuspected vulnerability of this population. What pharmacists should know about the Zika virusCases have been identified in the U.S. Now summer is coming, and this virus is most commonly transmitted by mosquitoes, so it is expected to spread more widely.